Table 3. Multivariate analysis of progression-free survival and overall survival in 176 patients with advanced lung adenocarcinoma.
| Parameter | Progression-free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| Hazard ratio(exp. B) | 95%CI | P value | Hazard ratio(exp. B) | 95%CI | P value | |
| SUVmaxWBR≥16.14 | 1.466 | 1.043–2.061 | 0.280 | 1.381 | 0.976–1.952 | 0.068 |
| TLGT≥104.65 | 1.001 | 0.706–1.419 | 0.995 | |||
| TLGWBR≥259.85 | 1.896 | 1.296–2.775 | 0.001 | 1.579 | 1.089–2.289 | 0.016 |
| EGFR(-) | 1.763 | 1.262–2.462 | 0.001 | 2.502 | 1.773–3.530 | 0.000 |
| Serum LDH (high) | 2.021 | 1.294–3.156 | 0.002 | 1.620 | 1.007–2.606 | 0.047 |
| ECOG performance status(0/1) | 1.381 | 0.965–1.975 | 0.077 | 1.185 | 0.814–1.727 | 0.375 |
| Sex (male) | 0.722 | 0.516–1.012 | 0.058 | |||
Abbreviations: SUVmaxWBR: the maximum SUVmax of all selected lesions in whole body determined using the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; TLGT: primary tumor total lesion glycolysis (TLG); TLGWBR: whole-body total TLG determined using the RECIST 1.1 criteria; EGFR: epidermal growth factor receptor; ECOG: Eastern Cooperative Oncology Group.